Shares of Sage Therapeutics soared a lot more than 60 percent found in premarket trading on Thursday following the company announced positive results in the screening a significant depressive disorder (MDD) treatment.
Sage said in a launching that 64 percent of individuals achieved MDD remission working with the SAGE-217 drug found in the 15th day of treatment.
This can be the second successful drug trial lead to as many months for Sage. On Nov. 9, the company said brexanolone – a drug aimed at treating average and severe postpartum depression – met its definitive goal in two late-level studies. The stock shot up 54.2 percent that day and is up 44.1 percent over the past month.
“These very encouraging info suggest the potential of SAGE-217 in the treating MDD along with other mood-related disorders that we may pursue,” CEO Jeff Jonas said in a statement. “The great activity and safety results of SAGE-217 in MDD support advancing this program into later stage clinical development.”